CHRNChronoScale Corporation

$14.78+201% 1Y
Latest close: below its 200-day averageOct 23, 2026what changed →

Is the business good?

Watch

More warning than reassurance: 3 of 9 health tests passed and margins compressing.

2 to watch, 2 without data
Fundamental health (F-score)3 / 9SEC EDGAR · May 31, 2026

Weak, deteriorating fundamentals. Nine pass/fail tests of year-over-year health from the filings.

Margin direction, 3 years−58.4 ptsderived

Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

Customers and suppliers

Who buys from CHRN and who it buys from, as the companies report it.

100%of revenue comes from customer A
Customerswho buys
Supplierswho it buys from

None disclosed.

A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; CHRN’s own figures are from its FY2026 10-K. Smaller customers and suppliers go unreported.

On our screens:Stocks with no debt